Improved Survival in FLT3-Mutated Acute Myeloid Leukemia

Combining the FLT3 inhibitor quizartinib with frontline chemotherapy improved survival compared with placebo, with or without allogeneic stem-cell consolidation.

Patients with acute myeloid leukemia (AML) and FMS-like tyrosine kinase 3 (FLT3) internal tandem duplication (ITD) mutations have a poor prognosis with standard induction chemotherapy but improved outcomes with the use of a FLT3 inhibitor and allogeneic stem-cell transplantation (alloSCT). Investigators now report the results of a phase 3, industry-sponsored, multinational, double-blind trial in patients with newly diagnosed AML and FLT3-ITD mutations. A total of 539 patients (median age, 56) were randomized to the once-daily oral FLT3 inhibitor quizartinib or placebo, each given in combination with induction and consolidation chemotherapy followed by up to 3 years of maintenance quizartinib or placebo. Patients with a suitable donor also u…

Reviewing Author

Michael E. Williams, MD, ScM

Disclosures

Consultant/Advisory BoardAbbVie; AstraZeneca; Beigene; Janssen; Pharmacyclics

Grant/Research SupportJanssen

Editorial BoardsAmerican Board of Internal Medicine (ABIM) Hematology Longitudinal Knowledge Approval Committee

Michael E. Williams, MD, ScM

Disclosures

Consultant/Advisory BoardAbbVie; AstraZeneca; Beigene; Janssen; Pharmacyclics

Grant/Research SupportJanssen

Editorial BoardsAmerican Board of Internal Medicine (ABIM) Hematology Longitudinal Knowledge Approval Committee

Improved Survival in FLT3-Mutated Acute Myeloid Leukemia

Topics

Reviewing Author